Investment Q&A

Q: Hello team. I am currently creating a short list for adding another U.S. equity position. Do you happen to have a short list of 3-5 U.S. equities you find attractive? I generally prefer mid cap companies with an ROE north of 18% and ROE/PE = 1.5 or greater.

Thank you,

Q: I'm concerned that aapl will become another blackberry with ever declining revenues and earnings disappointments. Do you think growth catalysts are on the horizon?

Q: How would you rate its stewardship/long term prospects?

Q: Hi are you able to correlate this sector developmenthttp://www.telegraph.co.uk/business/2016/07/24/gambling-groups-rank-and-888-in-takeover-bid-for-william-hill/
to NYX's pull back
No position , but wondering if sell off is overdone

Q: The following is a list of stock that I own showing the losses of each. Alta Gas(ALA) 32% Loss - Enerplus (ERF) 64% loss - Exco Tech(XTC)15% Loss - Gluskin (/GS) 32% loss -Painted Pony(PPY) 27% loss - Pur Tech(PUR) 27% loss and Surge(SGY)68% loss. Losses shown include dividends but I think all these companies have cut the dividends since I purchased them years ago. Question: Would you keep these or sell them now and purchase other stocks with better dividends. ? If you think these should be sold could you recommend a few. Thanks Ernie

Q: Hi please give me your opinion on Dragonwave.Had some recent volatility.

Q: Any news on Ithaca? It's down big so far today.

Q: Can I get your comments on this small REIT. How does its balance sheet look, what do you think of the management team, including the private equity firm involved, and how do you like (or not) the prospects. I would want it as a 5 year hold for income and some growth. Thanks.

Q: Can I have your opinion on AmSurg. It's on a high growth projectory and seems reasonably valued. Also how concerned should I be about it's heavy reliance on third party reimbursments(medicare and medicade) and debt level.
Thank-you.

Q: Do you believe that this is a good price point to enter a position. The stock looks to be basing and perhaps technically at least may be on the upswing. Thanks.

Q: This company seems well managed and has a decent balance sheet and may have good growth potential. Have you formed an opinion on it yet? I was thinking of entering in to a position. Thanks.

Q: How would you compare INO.UN and Drg.un as far as sustaining the dividend and some growth in Europe ?

Q: Could I get your opinion of the new BIP.UN preferred issue (series 5, reset with floor of 5.35%)? Would you agree with the S&P rating of P-2 low? I already hold both BIP.UN and BEP.UN in the Brookfield group. What would you consider to be the maximum percentage (based on total portfolio value) for BIP.UN + BIP pfd, and would you include BEP.UN in the total or view it as completely different, regardless of ultimate ownership?

Thank-you

Q: Please suggest an emerging market infrastructure etf priced in Canadian dollars. Thank you.

Q: I am considering initiating a position in Edgefront. It is a HIGH yield small cap REIT that trades on the Venture. It is an owner operator of commercial real estate properties in Western Canada and Atlantic Canada with a primary focus on industrial properties. I currently own 3500 units of Pure Industrial (AAR). I feel that AAR may be nearing the top end of its market price, so am considering taking some profits and investing them in ED.UN. I would appreciate your thoughts on this potential move.

Q: Any thoughts on Atlassian? (ticker is 'TEAM' on the Nasdaq)? I work in the software industry and I know that their products are fantastic and growing in popularity with large companies. Is it too early to get in as an investment?

Q: GBX seems cheap-rising trend. Has the correction relative to loss of tank-car business been overdone? Would you consider this a buy?

Thanks Jim

Q: Hello team. I currently have a small position in Antibe Therapeutics and considering adding more. This is a stage 2 drug company. No profit and sales really that tie in to the real story of the drug being created at the moment. Essentially they are trying to create a pain medication that will compete with the likes of Advil/Tylenol without the negative side effects of damaging the stomach lining and creating ulcers. The most interesting component is that amount of activity of old Paladin Labs/ new Knight Therapeutics people moving in and out of the company, setting up acquisitions and financing deals. Considering you guys cover Knight I was wondering if you had any further analysis or information on Antibe or the financing deals that Knight puts together? Or perhaps you could criticize or add to my qualitative analysis for other areas I should be concerned about?

Pros:
From what I can tell it's the only other company that Johnathan Goodman holds a position in besides Knight.
In the 50% region of insider ownership.
The fact they acquired a sales force shows confidence.

Cons:
One patient got something similar to Jondis, this forced the company back to the drawing board. If the product is not considered safer than Advil, it will have a hard time selling.
Further dilution will have to occur to proceed in product testing.

Q: I realize that different sectors likely have different ratios to analyze fundamentals but in general what do you consider the most important ratios to look at and what range is good vs bad - such as PE, Price to Cash Flow, Price to Sales, et.
Thank you.

Q: Looking to initiate a 3 to 5 year position in either xmm or xec. Which do you prefer and why? Thanx.